| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LION BIOTECHNOLOGIES INC | 2 | Q2 2015 | 99.4% |
| PTC THERAPEUTICS INC | 2 | Q4 2013 | 100.0% |
| CELGENE CORP | 2 | Q3 2013 | 76.5% |
| ONCOTHYREON INC | 2 | Q2 2015 | 3.5% |
| 0 | 2 | Q2 2014 | 0.0% |
| ARTHROCARE CORP | 1 | Q2 2013 | 23.5% |
View Ayer Capital Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Lion Biotechnologies, Inc. | May 20, 2015 | 2,823,333 | 6.3% |
| Genesis Biopharma, Inc | June 03, 2013 | 560,401,150 | 40.5% |
| InspireMD, Inc. | May 06, 2013 | 855,924 | 2.8% |
| PEREGRINE PHARMACEUTICALS INC | May 06, 2013 | 643,935 | 0.5% |
| BIOSPECIFICS TECHNOLOGIES CORPSold out | March 22, 2013 | 0 | 0.0% |
| ACCESS PHARMACEUTICALS INC | February 15, 2013 | 1,207,417 | 5.0% |
| Celsion CORP | February 15, 2013 | 1,747,145 | 5.0% |
| ImmunoCellular Therapeutics, Ltd. | February 15, 2013 | 2,089,088 | 4.1% |
| INSITE VISION INC | February 15, 2013 | 6,584,357 | 5.0% |
| ONCOSEC MEDICAL Inc | February 15, 2013 | 4,411,609 | 5.0% |
View Ayer Capital Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2015-08-14 |
| 144 | 2015-06-02 |
| 13F-HR | 2015-05-20 |
| SC 13G/A | 2015-05-20 |
| 4 | 2015-05-08 |
| 13F-HR | 2014-08-14 |
| 3/A | 2014-07-23 |
| 4 | 2014-07-23 |
| 5 | 2014-07-23 |
| 13F-HR | 2014-05-15 |
View Ayer Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.